Kineta, Merck strike deal to pair anti-VISTA antibody with Keytruda Business, R&D, Therapeutics Kineta, Inc. struck a collaboration deal with Merck to pair its anti-VISTA monoclonal antibody with Keytruda (pembrolizumab) as a potential treatment for advanced solid tumors, the companies announced Monday. Read more October 17, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/01/Merck-Dives-Deep-into-AI-with-610-Million-Absci-Pact-BioSPace-1-7-22.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-10-17 09:25:002022-10-17 10:29:33Kineta, Merck strike deal to pair anti-VISTA antibody with Keytruda
